The entire transaction, legally disclosed in a filing with Securities & Exchange Commission, was a total of $64,500.
Piper Jaffray Cos. has also increased Amsurg’s target price from $36 to $42. Analysts with Deutsche Bank have raised their target price for the company from $39 to $45.
More Articles on Transactions and Valuation Issues:
Medical Facilities Corporation Announces October Dividend
What to Consider Before Selling an ASC
Key Observations on ASC Transactions in 2013
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
